YOLFTbeta
Atrys Health SL

Atrys Health SL

ATRY · MC · Healthcare / Biotechnology

2.73EUR+0.07 (+2.63%)

Price History

Full chart

Market Stats

Previous Close2.66
Open2.69
Day Range2.66 – 2.74
52-Week Range2.31 – 3.59
Volume152.02K
Market Cap195.49M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.63
Dividend Yield0.00%
Beta0.57
50-Day Avg2.62
200-Day Avg2.76

About

Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medicine. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; telediagnosis activities in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and genetic counselling; and diagnostic reports and genetic tests. It also provides telemedicine services, such as teleradiology, telecardiology, teleoncology, teledermatology, teleophthalmology, and teleconsultations; prevention plans for companies, which includes training plans on occupational risk prevention; Smart Data, a technological database for healthcare; and research and development services. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Marian Isach Gabaldón
  • Employees763
  • HeadquartersCalle Velázquez, number 157, Madrid, Spain, 28002, Spain
  • Websitehttps://www.atryshealth.com

Leadership

  • Ms. Marian Isach GabaldónCEO & Executive Director
  • Dr. Carlos Cordon-CardoFounder & Scientific Vice President
  • Dr. Zvi FuchsFounder and Medical Vice President
  • Alberto IriondoChief Financial Officer
  • Luis DuranGlobal Chief Technology Officer
  • Ms. Gabriela Camunas CaruanaGeneral Counsel
  • Roberto LapiezaSales Director
  • Helena BorràsChief People Officer
  • Ms. María Rosa González SansManaging Director of Prevention
  • Mr. Alberto Castaneda GonzalezSecretary

Financials

Income Statement

Currency: EUR2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.08M1.02M1.09M2.87M5.96M8.03M7.29M14.84M33.81M121.01M158.37M201.57M212.74M141.01M
Growth (%)--5.59%+6.94%+163.02%+108.06%+34.66%-9.16%+103.41%+127.87%+257.94%+30.87%+27.28%+5.54%-33.72%
Cost of Revenue2.01M1.95M1.00M759.40K3.53M4.44M421.78K2.64M21.41M20.12M32.48M59.80M67.36M79.66M
Gross Profit-925.81K-927.06K87.46K2.11M2.43M3.59M6.87M12.20M12.40M100.89M24.20M141.77M145.38M61.35M
Gross Margin-85.78%-90.99%8.03%73.50%40.80%44.67%94.22%82.21%36.68%83.37%15.28%70.33%68.34%43.51%
Operating Expense-1.01M-805.88K-365.52K1.89M1.96M2.97M6.10M10.98M12.63M115.91M31.17M143.35M155.94M70.37M
Operating Income79.59K-121.17K452.98K213.59K475.03K615.04K769.96K1.21M-230.00K-15.01M-6.97M-1.58M-10.55M-9.02M
Operating Margin7.37%-11.89%41.57%7.45%7.97%7.66%10.56%8.19%-0.68%-12.41%-4.40%-0.78%-4.96%-6.40%
EBITDA526.35K186.71K661.34K1.88M225.54K981.47K1.96M3.17M6.68M5.87M16.63M31.91M19.07M-9.96M
EBITDA Margin48.77%18.32%60.70%65.74%3.78%12.22%26.91%21.38%19.77%4.85%10.50%15.83%8.96%-7.07%
Net Income681.81K336.53K320.20K1.29M63.04K290.94K11.98K-104.78K-5.55M-23.20M-23.15M-45.59M-31.77M-100.30M
Net Income Margin63.17%33.03%29.39%45.18%1.06%3.62%0.16%-0.71%-16.41%-19.17%-14.62%-22.62%-14.94%-71.13%
R&D756.71K629.30K95.12K92.24K275.73K300.80K301.17K1.63M1.26M1.94M1.67M3.12M--
R&D as % of Total Revenue70.11%61.76%8.73%3.22%4.62%3.75%4.13%11.00%3.73%1.60%1.05%1.55%--
Interest Expense304.00K352.62K358.63K527.03K685.98K1.01M609.44K1.06M2.14M11.03M14.53M33.40M23.50M19.02M
Interest Expense % of Total Revenue28.17%34.61%32.91%18.39%11.50%12.54%8.36%7.14%6.32%9.12%9.18%16.57%11.04%13.49%

Balance Sheet

Currency: EUR2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets18.29M18.87M19.53M26.10M30.57M40.20M53.69M88.04M175.78M565.63M705.28M629.00M584.19M494.04M
Total Liabilities12.24M12.25M12.61M14.40M16.31M16.90M27.25M48.09M100.45M291.65M367.71M339.12M330.95M342.08M
Total Equity6.06M6.62M6.92M10.29M14.26M23.30M26.44M39.95M71.38M274.03M337.63M289.87M253.10M151.86M
Cash454.14K690.58K448.01K915.40K2.85M9.27M9.76M8.33M17.48M35.13M34.30M41.83M20.36M13.07M
Total Debt10.67M10.86M11.27M13.40M4.35M11.19M18.19M35.34M71.46M154.95M241.22M254.00M166.13M257.87M
Net Debt10.22M10.17M10.82M12.48M1.50M1.92M8.43M27.01M53.98M169.39M224.44M212.17M145.76M244.80M

Cash Flow

Currency: EUR2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---409.89K-793.63K1.32M-913.68K1.08M-1.40M4.69M-15.43M-1.09M3.00M-1.56M
Investing Cash Flow----2.52M-1.79M-3.42M-7.67M-21.10M-52.08M-2.45M-80.59M395.00K-12.95M-12.59M
Financing Cash Flow---2.56M5.43M8.52M9.08M18.58M62.63M14.08M94.77M8.19M-11.51M11.28M
Capital Expenditure0002.52M1.59M344.18K2.29M4.80M5.29M8.57M15.16M6.25M13.14M12.52M
Free Cash Flow----2.11M-2.38M972.55K-3.20M-3.72M-6.69M-3.87M-30.59M-547.00K-10.14M-14.08M
FCF to OCF----515.80%299.78%73.86%350.34%-343.20%478.96%-82.51%198.23%50.05%-338.37%902.89%

Earnings

Report DateOct 25, 2016Apr 28, 2017Oct 26, 2017Apr 25, 2018Oct 23, 2018Apr 29, 2019Oct 28, 2019Apr 30, 2020Oct 29, 2020May 1, 2021Oct 29, 2021Mar 30, 2022Sep 30, 2022Mar 29, 2023Oct 24, 2023Mar 26, 2024
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual0.05-0.020.010.020.01-0.010.01-0.01-0.03-0.04-0.08-0.32-0.05-0.380.000.00
Surprise----------------
Timing---Pre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hours--Pre-marketAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap195.49M
Enterprise Value319.99M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.32
Price / Book1.45
EPS-0.63
Book Value1.94
Revenue (TTM)147.68M
Gross Profit (TTM)24.58M
EBITDA249.00K
Profit Margin-65.95%
Operating Margin-0.90%
Return on Equity-24.57%
Return on Assets-1.08%
Shares Outstanding75.92M
Shares Float40.09M
Beta0.57
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%